Compare Stocks

Date Range: 

 Applied Genetic TechnologiesFennec PharmaceuticalsVoyager TherapeuticsGamida CellLogicBio Therapeutics
SymbolNASDAQ:AGTCNASDAQ:FENCNASDAQ:VYGRNASDAQ:GMDANASDAQ:LOGC
Price Information
Current Price$4.26$6.77$4.73$6.44$4.59
52 Week RangeBuyBuyHoldBuyBuy
MarketRank™
Overall Score1.61.41.71.41.3
Analysis Score3.53.53.13.53.5
Community Score3.02.52.62.72.4
Dividend Score0.00.00.00.00.0
Ownership Score0.80.81.70.00.8
Earnings & Valuation Score0.60.01.30.60.0
Analyst Ratings
Consensus RecommendationBuyBuyHoldBuyBuy
Consensus Price Target$17.58$13.50$10.55$20.25$17.33
% Upside from Price Target312.75% upside99.41% upside123.04% upside214.44% upside277.63% upside
Trade Information
Market Cap$182.56 million$178.90 million$182.60 millionN/A$155.98 million
Beta2.210.091.11.931.17
Average Volume2,280,821107,634558,021697,944139,797
Sales & Book Value
Annual Revenue$2.45 million$170,000.00$171.13 millionN/A$3.45 million
Price / Sales74.341,035.531.04N/A42.79
CashflowN/AN/A$1.06 per shareN/AN/A
Price / CashN/AN/A4.47N/AN/A
Book Value$2.76 per share$1.12 per share$4.12 per share$1.44 per share$1.93 per share
Price / Book1.546.041.15N/A2.38
Profitability
Net Income$-45,890,000.00$-18,110,000.00$36.74 million$-72,700,000.00$-32,620,000.00
EPS($2.17)($0.76)$0.98($1.66)($1.29)
Trailing P/E RatioN/AN/A4.59N/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A24.66%N/AN/A
Return on Equity (ROE)-90.61%-62.70%29.50%-100.66%-80.55%
Return on Assets (ROA)-62.13%-57.35%14.76%-55.78%-54.90%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.10%N/AN/A0.82%0.14%
Current Ratio6.83%9.62%7.10%8.97%8.58%
Quick Ratio6.83%9.62%7.10%8.97%8.58%
Ownership Information
Institutional Ownership Percentage43.50%55.24%69.40%N/A54.74%
Insider Ownership Percentage7.50%9.68%23.90%N/A23.40%
Miscellaneous
Employees83N/A17711039
Shares Outstanding42.76 million26.00 million37.73 million24.22 million32.16 million
Next Earnings Date9/8/2021 (Estimated)8/4/2021 (Estimated)8/9/2021 (Estimated)8/10/2021 (Estimated)8/9/2021 (Estimated)
OptionableOptionableOptionableOptionableNot OptionableNot Optionable
SourceHeadline
LogicBio Therapeutics (NASDAQ:LOGC) Coverage Initiated by Analysts at HC WainwrightLogicBio Therapeutics (NASDAQ:LOGC) Coverage Initiated by Analysts at HC Wainwright
americanbankingnews.com - June 7 at 7:08 AM
LogicBio Therapeutics Inc (LOGC)LogicBio Therapeutics Inc (LOGC)
investing.com - June 5 at 7:27 PM
Chardan Capital Reaffirms "Buy" Rating for LogicBio Therapeutics (NASDAQ:LOGC)Chardan Capital Reaffirms "Buy" Rating for LogicBio Therapeutics (NASDAQ:LOGC)
americanbankingnews.com - June 2 at 1:04 PM
BRIEF-Logicbio Therapeutics Announces First Patient Dosed In Groundbreaking Phase 1/2 Sunrise Clinical Trial For The Treatment Of Pediatric Patients Suffering From ...BRIEF-Logicbio Therapeutics Announces First Patient Dosed In Groundbreaking Phase 1/2 Sunrise Clinical Trial For The Treatment Of Pediatric Patients Suffering From ...
msn.com - June 2 at 8:40 AM
LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic AcidemiaLogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic Acidemia
finance.yahoo.com - June 2 at 8:40 AM
LogicBio Therapeutics to Participate in Upcoming Investor ConferencesLogicBio Therapeutics to Participate in Upcoming Investor Conferences
finance.yahoo.com - June 1 at 7:13 PM
LogicBio Therapeutics Promotes Daniel Gruskin, MD, to Chief Medical Officer and Announces Additional Leadership AppointmentsLogicBio Therapeutics Promotes Daniel Gruskin, MD, to Chief Medical Officer and Announces Additional Leadership Appointments
finance.yahoo.com - May 19 at 8:21 AM
LogicBio Therapeutics (NASDAQ:LOGC) Stock Price Has Reduced 22% In The Past YearLogicBio Therapeutics' (NASDAQ:LOGC) Stock Price Has Reduced 22% In The Past Year
finance.yahoo.com - May 17 at 2:38 PM
LogicBio Therapeutics: Q1 Earnings SnapshotLogicBio Therapeutics: Q1 Earnings Snapshot
stamfordadvocate.com - May 10 at 8:20 AM
LogicBio Therapeutics Strengthens Management Team with Key AppointmentsLogicBio Therapeutics Strengthens Management Team with Key Appointments
finance.yahoo.com - May 10 at 8:20 AM
LogicBio Therapeutics Reports First Quarter Year 2021 Financial Results and Provides Business UpdateLogicBio Therapeutics Reports First Quarter Year 2021 Financial Results and Provides Business Update
finance.yahoo.com - May 10 at 8:20 AM
LogicBio Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual MeetingLogicBio Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
finance.yahoo.com - May 4 at 9:59 AM
LogicBio Announces Presentation of Retrospective Study of Disease Course in Pediatric Patients with Severe Methylmalonic AcidemiaLogicBio Announces Presentation of Retrospective Study of Disease Course in Pediatric Patients with Severe Methylmalonic Acidemia
finance.yahoo.com - May 3 at 6:49 PM
BRIEF-LogicBio Therapeutics Announces Strategic Collaboration And Option Agreement With Canbridge Pharmaceuticals Leveraging Gene Editing And Gene Delivery PlatformsBRIEF-LogicBio Therapeutics Announces Strategic Collaboration And Option Agreement With Canbridge Pharmaceuticals Leveraging Gene Editing And Gene Delivery Platforms
msn.com - April 27 at 2:11 PM
LogicBio Therapeutics, CANbridge Ink Partnership For Development Of Gene Therapy CandidatesLogicBio Therapeutics, CANbridge Ink Partnership For Development Of Gene Therapy Candidates
finance.yahoo.com - April 27 at 2:11 PM
LogicBio Collaborates With CANbridge Pharma; Grants Option To License LB-001 In Greater ChinaLogicBio Collaborates With CANbridge Pharma; Grants Option To License LB-001 In Greater China
markets.businessinsider.com - April 27 at 9:10 AM
LogicBio Therapeutics Announces Research Collaboration with Daiichi SankyoLogicBio Therapeutics Announces Research Collaboration with Daiichi Sankyo
prnewswire.com - April 27 at 9:10 AM
LogicBio Therapeutics Announces Strategic Collaboration and Option Agreement with CANbridge Pharmaceuticals Leveraging Gene Editing and Gene Delivery PlatformsLogicBio Therapeutics Announces Strategic Collaboration and Option Agreement with CANbridge Pharmaceuticals Leveraging Gene Editing and Gene Delivery Platforms
finance.yahoo.com - April 27 at 9:10 AM
What Percentage Of LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Shares Do Insiders Own?What Percentage Of LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Shares Do Insiders Own?
nasdaq.com - April 24 at 6:42 PM
Health Check: How Prudently Does LogicBio Therapeutics (NASDAQ:LOGC) Use Debt?Health Check: How Prudently Does LogicBio Therapeutics (NASDAQ:LOGC) Use Debt?
finance.yahoo.com - March 17 at 12:29 PM
LogicBio Therapeutics Reports Full Year 2020 Financial Results and Provides Business UpdateLogicBio Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update
finance.yahoo.com - March 15 at 5:56 PM
LogicBio Announces Extension Of Collaboration With Children’s Medical Research InstituteLogicBio Announces Extension Of Collaboration With Children’s Medical Research Institute
apnews.com - January 7 at 12:40 PM
LogicBio Announces Extension Of Collaboration With Childrens Medical Research InstituteLogicBio Announces Extension Of Collaboration With Children's Medical Research Institute
finance.yahoo.com - January 7 at 12:40 PM
LogicBio Therapeutics to Present at 39th Annual J.P. Morgan Healthcare ConferenceLogicBio Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 6 at 11:32 AM
LogicBio Therapeutics Inc. Regi (0IF.SG)LogicBio Therapeutics Inc. Regi (0IF.SG)
sg.finance.yahoo.com - January 1 at 10:36 PM
DateCompanyBrokerageAction
3/1/2021Applied Genetic TechnologiesStifel NicolausInitiated Coverage
2/2/2021Applied Genetic TechnologiesHC WainwrightBoost Price Target
2/1/2021Applied Genetic TechnologiesRoth CapitalBoost Price Target
11/20/2020Applied Genetic TechnologiesBerenberg BankReiterated Rating
7/22/2020Applied Genetic TechnologiesChardan CapitalReiterated Rating
6/22/2020Applied Genetic TechnologiesCantor FitzgeraldInitiated Coverage
1/24/2020Applied Genetic TechnologiesJanney Montgomery ScottReiterated Rating
1/9/2020Applied Genetic TechnologiesWedbushReiterated Rating
1/9/2020Applied Genetic TechnologiesBMO Capital MarketsBoost Price Target
5/28/2021Fennec PharmaceuticalsMaxim GroupReiterated Rating
4/21/2021Fennec PharmaceuticalsCraig HallumInitiated Coverage
10/11/2018Fennec PharmaceuticalsThe Goldman Sachs GroupInitiated Coverage
10/11/2018Fennec PharmaceuticalsDawson JamesInitiated Coverage
5/13/2021Voyager TherapeuticsRobert W. BairdReiterated Rating
4/19/2021Voyager TherapeuticsMorgan StanleyLower Price Target
2/3/2021Voyager TherapeuticsBTIG ResearchDowngrade
1/13/2021Voyager TherapeuticsCanaccord GenuityReiterated Rating
12/23/2020Voyager TherapeuticsRaymond JamesDowngrade
11/11/2020Voyager TherapeuticsOppenheimerDowngrade
11/10/2020Voyager TherapeuticsWells Fargo & CompanyDowngrade
5/13/2020Voyager TherapeuticsNomuraReiterated Rating
3/30/2020Voyager TherapeuticsNomura SecuritiesLower Price Target
3/9/2021Gamida CellPiper SandlerLower Price Target
3/9/2021Gamida CellNeedham & Company LLCLower Price Target
6/30/2020Gamida CellEvercore ISIInitiated Coverage
9/20/2019Gamida CellJMP SecuritiesInitiated Coverage
11/21/2018Gamida CellCIBCInitiated Coverage
3/1/2021LogicBio TherapeuticsWilliam BlairReiterated Rating
11/13/2018LogicBio TherapeuticsBarclaysInitiated Coverage
(Data available from 6/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.